This contract expires in 105 days (Sep 24, 2026).
JACKSON LABORATORY - NICHD: R&D: TO PRODUCE, POTENTIALLY ACQUIRE, MAINTAIN, AND DISTRIBUTE MOUSE MODELS FOR CYTOGENETIC RESEARCH, SPECIFICALLY MODELS FOR DOWN SYNDROME (HUMAN TRISOMY FOR CHROMOSOME 21): SEVERABLE
Key Details
Description
NICHD: R&D: TO PRODUCE, POTENTIALLY ACQUIRE, MAINTAIN, AND DISTRIBUTE MOUSE MODELS FOR CYTOGENETIC RESEARCH, SPECIFICALLY MODELS FOR DOWN SYNDROME (HUMAN TRISOMY FOR CHROMOSOME 21): SEVERABLE
Context & Analysis
On Mar 4, 2026, Department of Health and Human Services obligated $649,999 to JACKSON LABORATORY for nichd: r&d: to produce, potentially acquire, maintain, and distribute mouse models for cytogenetic research, specifically models for down syndrome (human trisomy for chromosome 21): severable. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: not competed with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in BAR HARBOR, ME. The contract is scheduled through Sep 24, 2026 — approximately 4 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.